| Desmopressin |
Increases levels of
enzymes that are deficient in this condition.
These enzymes are necessary for formation of blood
clots. |
0.3 micrograms/kg by intravenous
or subcutaeous administration (maximum 20
micrograms) diluted in 50 mL of normal saline
infused over 20 to 30 minutes.Alternative
is 150-300 micrograms by intranasal spray
(1 spray in each nostril).
|
| Von Willebrand factor
concentrates |
Direct replacement
of deficient clotting factors are indicated in
more severe types of this disease (Type 3 VWD
and severe Type 2a and 2b VWD). |
20 to 30 International
Units per kg of body weight by intravenous infusion
as labeled to raise the plasma concentration of
ristocetin factor to 50 to 100 percent. |
| Aminocaproic acid |
Used to prevent the
breakdown of blood clots. |
50 mg per kg of body
weight by mouth or by intravenous injection four
times a day. |
| Tranexaminic acid |
Used to prevent the
breakdown of blood clots, and thereby decrease
bleeding. |
25 mg per kg of body
weight by mouth or by intravenous injection three
times a day. |
| Topical thrombin |
Used to control minor
bleeding |
1000-2000 units per
milliliter of solution by direct application to
bleeding area. Use 100 units per milliliter for
bleeding from skin or mucosal surfaces |
| Intravenous immune
globulin (IVIG) |
Used in patients with
VWD who have not responded well to desmopressin
and also have another autoimmune condition. |
1 gm per kg of body
weight by intravenous administration once daily
for two days. |